ELDN 10-Q: SEC filing
Eledon Pharmaceuticals
Filed with the SEC on · accession 0001193125-26-458564
ELDN filed a 10-Q (quarterly report) with the SEC on Nov 12, 2026. The quarterly report: unaudited results for the quarter plus management’s comments. The stock moved -11.4% by the first close after the filing.
Summary of the filing
Eledon Pharmaceuticals filed its Q3 2026 Form 10-Q, reporting quarterly financial results and disclosures including license agreements with Lonza Sales AG and the ALS Therapy Development Foundation, along with details of prior equity financings and warrants.
Key details
How ELDN stock reacted
Close before
$2.67
Nov 11, 2026
First close after
-11.42%
$2.37
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for ELDN, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for ELDN?
Click hereFrequently asked questions
What did ELDN file with the SEC on Nov 12, 2026?
ELDN filed a 10-Q (SEC filing). Eledon Pharmaceuticals filed its Q3 2026 Form 10-Q, reporting quarterly financial results and disclosures including license agreements with Lonza Sales AG and the ALS Therapy Development Foundation, along with details of prior equity financings and warrants.
How do I read a 10-Q?
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
How did ELDN stock react to this filing?
ELDN closed at $2.67 before the filing and $2.37 on Nov 12, 2026 (-11.42%).
Other ELDN SEC filings
Get alerts when ELDN files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days